📊 ACXP Key Takeaways
Is Acurx Pharmaceuticals, Inc. (ACXP) a Good Investment?
Acurx is a pre-revenue pharmaceutical company with negative operating cash flow of -6.8M and widening losses, indicating significant cash burn without commercial traction. The company is entirely dependent on existing cash reserves (7.6M) to fund operations, which at current burn rates provides less than 14 months of runway. With no revenue generation, no product commercialization evidence, and deteriorating financial metrics, fundamental viability is severely compromised.
Acurx Pharmaceuticals appears to be a pre-revenue development-stage biotech with no commercial revenue, persistent operating losses, and negative operating cash flow, which makes the fundamental profile weak despite year-over-year EPS improvement. The balance sheet is currently supported by cash and no long-term debt, but cash burn relative to its cash balance suggests limited runway unless operating performance improves materially or new capital is raised.
Why Buy Acurx Pharmaceuticals, Inc. Stock? ACXP Key Strengths
- Strong liquidity position with 7.6M cash and 2.54x current ratio
- No debt obligations providing financial flexibility
- Positive EPS improvement year-over-year (though still deeply negative)
- Debt-free balance sheet with 0.00x debt-to-equity reduces financial distress risk
- Cash of $7.56M covers most of the asset base and supports near-term operations
- Positive stockholders' equity of $5.27M provides some balance sheet cushion
ACXP Stock Risks: Acurx Pharmaceuticals, Inc. Investment Risks
- Pre-revenue stage with zero commercial product sales and no path to profitability visible
- Severe cash burn of -6.8M annually against limited cash reserves of only 7.6M (~13.8 months runway)
- Negative ROE of -151.2% and ROA of -103.6% indicate destructive capital deployment
- Complete lack of insider confidence demonstrated by zero Form 4 filings in last 90 days
- Operating losses of -8.1M with no gross profit or revenue to offset spending
- High dilution risk as company must issue equity to survive capital needs
- No reported revenue means the business has not yet demonstrated commercial viability
- Annual operating cash burn of $6.79M versus $7.56M cash implies a short funding runway
- ROE of -151.2% and ROA of -103.6% reflect very weak capital efficiency and ongoing losses
Key Metrics to Watch
- Monthly cash burn rate and remaining cash runway
- Clinical trial progress and regulatory milestones for pipeline candidates
- Revenue generation and product commercialization timeline
- Operating expense reduction and path to cash flow breakeven
- Quarterly cash burn relative to cash and equivalents
- Any transition from pre-revenue status to sustainable revenue generation
Acurx Pharmaceuticals, Inc. (ACXP) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 2.54x current ratio provides a solid financial cushion.
ACXP Profit Margin, ROE & Profitability Analysis
ACXP vs Healthcare Sector: How Acurx Pharmaceuticals, Inc. Compares
How Acurx Pharmaceuticals, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Acurx Pharmaceuticals, Inc. Stock Overvalued? ACXP Valuation Analysis 2026
Based on fundamental analysis, Acurx Pharmaceuticals, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Acurx Pharmaceuticals, Inc. Balance Sheet: ACXP Debt, Cash & Liquidity
ACXP Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Acurx Pharmaceuticals, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-17.45 indicates the company is currently unprofitable.
ACXP Revenue Growth, EPS Growth & YoY Performance
Acurx Pharmaceuticals, Inc. Dividends, Buybacks & Capital Allocation
ACXP SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Acurx Pharmaceuticals, Inc. (CIK: 0001736243)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ACXP
What is the AI rating for ACXP?
Acurx Pharmaceuticals, Inc. (ACXP) has a Combined AI Rating of SELL from Claude (STRONG SELL) and ChatGPT (SELL) with 88% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ACXP's key strengths?
Claude: Strong liquidity position with 7.6M cash and 2.54x current ratio. No debt obligations providing financial flexibility. ChatGPT: Debt-free balance sheet with 0.00x debt-to-equity reduces financial distress risk. Cash of $7.56M covers most of the asset base and supports near-term operations.
What are the risks of investing in ACXP?
Claude: Pre-revenue stage with zero commercial product sales and no path to profitability visible. Severe cash burn of -6.8M annually against limited cash reserves of only 7.6M (~13.8 months runway). ChatGPT: No reported revenue means the business has not yet demonstrated commercial viability. Annual operating cash burn of $6.79M versus $7.56M cash implies a short funding runway.
What is ACXP's revenue and growth?
Acurx Pharmaceuticals, Inc. reported revenue of N/A.
Does ACXP pay dividends?
Acurx Pharmaceuticals, Inc. does not currently pay dividends.
Where can I find ACXP SEC filings?
Official SEC filings for Acurx Pharmaceuticals, Inc. (CIK: 0001736243) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ACXP's EPS?
Acurx Pharmaceuticals, Inc. has a diluted EPS of $-5.32.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is ACXP a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Acurx Pharmaceuticals, Inc. has a SELL rating with 88% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is ACXP stock overvalued or undervalued?
Valuation metrics for ACXP: ROE of -151.2% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy ACXP stock in 2026?
Our dual AI analysis gives Acurx Pharmaceuticals, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ACXP's free cash flow?
Acurx Pharmaceuticals, Inc.'s operating cash flow is $-6.8M, with capital expenditures of N/A.
How does ACXP compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -151.2% (avg: 15%), current ratio 2.54 (avg: 2).